QQQ   325.93 (+2.79%)
AAPL   169.24 (+2.62%)
MSFT   289.16 (+2.43%)
META   178.34 (+5.82%)
GOOGL   119.70 (+2.63%)
AMZN   142.69 (+3.53%)
TSLA   883.07 (+3.89%)
NVDA   180.97 (+5.92%)
NIO   20.05 (+4.59%)
BABA   92.43 (+1.36%)
AMD   99.05 (+3.67%)
MU   61.40 (+3.80%)
T   18.01 (-0.50%)
CGC   3.29 (+14.63%)
GE   77.14 (+2.95%)
F   15.50 (+2.04%)
DIS   112.43 (+3.98%)
AMC   23.67 (+5.43%)
PYPL   98.91 (+4.69%)
PFE   49.95 (+0.34%)
NFLX   244.11 (+6.16%)
QQQ   325.93 (+2.79%)
AAPL   169.24 (+2.62%)
MSFT   289.16 (+2.43%)
META   178.34 (+5.82%)
GOOGL   119.70 (+2.63%)
AMZN   142.69 (+3.53%)
TSLA   883.07 (+3.89%)
NVDA   180.97 (+5.92%)
NIO   20.05 (+4.59%)
BABA   92.43 (+1.36%)
AMD   99.05 (+3.67%)
MU   61.40 (+3.80%)
T   18.01 (-0.50%)
CGC   3.29 (+14.63%)
GE   77.14 (+2.95%)
F   15.50 (+2.04%)
DIS   112.43 (+3.98%)
AMC   23.67 (+5.43%)
PYPL   98.91 (+4.69%)
PFE   49.95 (+0.34%)
NFLX   244.11 (+6.16%)
QQQ   325.93 (+2.79%)
AAPL   169.24 (+2.62%)
MSFT   289.16 (+2.43%)
META   178.34 (+5.82%)
GOOGL   119.70 (+2.63%)
AMZN   142.69 (+3.53%)
TSLA   883.07 (+3.89%)
NVDA   180.97 (+5.92%)
NIO   20.05 (+4.59%)
BABA   92.43 (+1.36%)
AMD   99.05 (+3.67%)
MU   61.40 (+3.80%)
T   18.01 (-0.50%)
CGC   3.29 (+14.63%)
GE   77.14 (+2.95%)
F   15.50 (+2.04%)
DIS   112.43 (+3.98%)
AMC   23.67 (+5.43%)
PYPL   98.91 (+4.69%)
PFE   49.95 (+0.34%)
NFLX   244.11 (+6.16%)
QQQ   325.93 (+2.79%)
AAPL   169.24 (+2.62%)
MSFT   289.16 (+2.43%)
META   178.34 (+5.82%)
GOOGL   119.70 (+2.63%)
AMZN   142.69 (+3.53%)
TSLA   883.07 (+3.89%)
NVDA   180.97 (+5.92%)
NIO   20.05 (+4.59%)
BABA   92.43 (+1.36%)
AMD   99.05 (+3.67%)
MU   61.40 (+3.80%)
T   18.01 (-0.50%)
CGC   3.29 (+14.63%)
GE   77.14 (+2.95%)
F   15.50 (+2.04%)
DIS   112.43 (+3.98%)
AMC   23.67 (+5.43%)
PYPL   98.91 (+4.69%)
PFE   49.95 (+0.34%)
NFLX   244.11 (+6.16%)
NASDAQ:VNDA

Vanda Pharmaceuticals - VNDA Stock Forecast, Price & News

$10.55
+0.28 (+2.73%)
(As of 08/10/2022 12:00 AM ET)
Add
Compare
Today's Range
$10.18
$10.56
50-Day Range
$9.31
$11.76
52-Week Range
$9.24
$21.44
Volume
376,957 shs
Average Volume
530,289 shs
Market Capitalization
$596.72 million
P/E Ratio
52.75
Dividend Yield
N/A
Price Target
$12.00

Vanda Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
13.7% Upside
$12.00 Price Target
Short Interest
Healthy
4.14% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.77
Upright™ Environmental Score
News Sentiment
-0.47mentions of Vanda Pharmaceuticals in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$114,183 Sold Last Quarter
Proj. Earnings Growth
53.33%
From $0.30 to $0.46 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.38 out of 5 stars

Medical Sector

295th out of 1,108 stocks

Pharmaceutical Preparations Industry

130th out of 542 stocks

VNDA stock logo

About Vanda Pharmaceuticals (NASDAQ:VNDA) Stock

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Vanda Pharmaceuticals Stock Down 2.4 %

VNDA opened at $10.27 on Wednesday. The business's fifty day simple moving average is $10.64 and its 200 day simple moving average is $11.28. The firm has a market cap of $580.88 million, a P/E ratio of 51.35 and a beta of 0.47. Vanda Pharmaceuticals has a 52 week low of $9.24 and a 52 week high of $21.44.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded shares of Vanda Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Friday, June 3rd.

Insider Buying and Selling

In other news, Director Stephen Ray Mitchell sold 2,700 shares of the company's stock in a transaction that occurred on Monday, June 13th. The stock was sold at an average price of $9.48, for a total value of $25,596.00. Following the sale, the director now directly owns 6,515 shares in the company, valued at approximately $61,762.20. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, Director Richard W. Dugan sold 6,500 shares of the business's stock in a transaction on Tuesday, May 31st. The shares were sold at an average price of $9.85, for a total value of $64,025.00. Following the sale, the director now owns 68,387 shares of the company's stock, valued at $673,611.95. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Stephen Ray Mitchell sold 2,700 shares of the company's stock in a transaction dated Monday, June 13th. The shares were sold at an average price of $9.48, for a total transaction of $25,596.00. Following the transaction, the director now owns 6,515 shares in the company, valued at approximately $61,762.20. The disclosure for this sale can be found here. Insiders have sold 11,439 shares of company stock worth $114,183 in the last three months. 6.10% of the stock is currently owned by insiders.

Receive VNDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vanda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VNDA Stock News Headlines

Vanda Pharmaceuticals Tops Q1 EPS by 12c
Earnings Outlook For Vanda Pharmaceuticals
Why Are Vanda Pharma Shares Plunging Today?
See More Headlines
Receive VNDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vanda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VNDA Company Calendar

Last Earnings
11/03/2021
Today
8/10/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:VNDA
CUSIP
92165910
Employees
278
Year Founded
2002

Price Target and Rating

Average Stock Price Forecast
$12.00
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+13.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$33.15 million
Pretax Margin
5.92%

Debt

Sales & Book Value

Annual Sales
$268.68 million
Cash Flow
$0.68 per share
Book Value
$9.06 per share

Miscellaneous

Free Float
53,111,000
Market Cap
$596.72 million
Optionable
Optionable
Beta
0.47

Social Links















VNDA Stock - Frequently Asked Questions

Should I buy or sell Vanda Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vanda Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" VNDA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VNDA, but not buy additional shares or sell existing shares.
View VNDA analyst ratings
or view top-rated stocks.

What is Vanda Pharmaceuticals' stock price forecast for 2022?

1 Wall Street analysts have issued 12 month price objectives for Vanda Pharmaceuticals' shares. Their VNDA share price forecasts range from $12.00 to $12.00. On average, they anticipate the company's stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 15.6% from the stock's current price.
View analysts price targets for VNDA
or view top-rated stocks among Wall Street analysts.

How have VNDA shares performed in 2022?

Vanda Pharmaceuticals' stock was trading at $15.69 at the beginning of the year. Since then, VNDA shares have decreased by 33.8% and is now trading at $10.38.
View the best growth stocks for 2022 here
.

Are investors shorting Vanda Pharmaceuticals?

Vanda Pharmaceuticals saw a drop in short interest in the month of July. As of July 15th, there was short interest totaling 2,490,000 shares, a drop of 41.4% from the June 30th total of 4,250,000 shares. Based on an average daily trading volume, of 524,900 shares, the days-to-cover ratio is currently 4.7 days. Approximately 4.6% of the company's shares are sold short.
View Vanda Pharmaceuticals' Short Interest
.

When is Vanda Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our VNDA earnings forecast
.

How were Vanda Pharmaceuticals' earnings last quarter?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) announced its quarterly earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.20 by $0.06. The biopharmaceutical company earned $70.10 million during the quarter, compared to analysts' expectations of $73.50 million. Vanda Pharmaceuticals had a trailing twelve-month return on equity of 2.19% and a net margin of 4.18%. During the same period in the prior year, the company earned $0.11 earnings per share.

What guidance has Vanda Pharmaceuticals issued on next quarter's earnings?

Vanda Pharmaceuticals issued an update on its FY 2022 earnings guidance on Wednesday, August, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $240.00 million-$280.00 million, compared to the consensus revenue estimate of $265.10 million.

What is Mihael H. Polymeropoulos' approval rating as Vanda Pharmaceuticals' CEO?

12 employees have rated Vanda Pharmaceuticals Chief Executive Officer Mihael H. Polymeropoulos on Glassdoor.com. Mihael H. Polymeropoulos has an approval rating of 24% among the company's employees. This puts Mihael H. Polymeropoulos in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Vanda Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vanda Pharmaceuticals investors own include FibroGen (FGEN), Zogenix (ZGNX), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Array Technologies (ARRY), Micron Technology (MU) and Novavax (NVAX).

What is Vanda Pharmaceuticals' stock symbol?

Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."

Who are Vanda Pharmaceuticals' major shareholders?

Vanda Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (4.47%), Pictet Asset Management SA (0.50%), Victory Capital Management Inc. (0.48%), State Board of Administration of Florida Retirement System (0.37%), Walleye Capital LLC (0.34%) and Royce & Associates LP (0.13%). Insiders that own company stock include Aranthan Jones II, Gian Piero Reverberi, Gunther Birznieks, James Patrick Kelly, Joakim Wijkstrom, Kevin Patrick Moran, Melissa Young, Mihael Hristos Polymeropoulos, Phaedra Chrousos, Richard W Dugan, Stephen Ray Mitchell, Thomas Watkins and Timothy Williams.
View institutional ownership trends
.

How do I buy shares of Vanda Pharmaceuticals?

Shares of VNDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vanda Pharmaceuticals' stock price today?

One share of VNDA stock can currently be purchased for approximately $10.38.

How much money does Vanda Pharmaceuticals make?

Vanda Pharmaceuticals (NASDAQ:VNDA) has a market capitalization of $587.10 million and generates $268.68 million in revenue each year. The biopharmaceutical company earns $33.15 million in net income (profit) each year or $0.20 on an earnings per share basis.

How many employees does Vanda Pharmaceuticals have?

The company employs 278 workers across the globe.

When was Vanda Pharmaceuticals founded?

Vanda Pharmaceuticals was founded in 2002.

How can I contact Vanda Pharmaceuticals?

Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVENUE NW SUITE 300 E, WASHINGTON DC, 20037. The official website for the company is www.vandapharma.com. The biopharmaceutical company can be reached via phone at (202) 734-3400, via email at pr@vandapharma.com, or via fax at 202-296-1450.

This page (NASDAQ:VNDA) was last updated on 8/10/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.